MIRVASO (brimonidine tartrate)
Mirvaso (brimonidine) topical gel, 0.33% is an alpha-adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema associated with rosacea in adults aged 18 years or older. It is designed to reduce the baseline facial redness that characterizes the condition rather than treating transient flushing or inflammatory lesions.
How MIRVASO Works
Brimonidine is a relatively selective alpha-2 adrenergic agonist. When applied topically, it reduces facial erythema through direct vasoconstriction of the small arteries and veins in the dermal vasculature.
Details
- Status
- Prescription
- First Approved
- 2013-08-23
- Patent Cliff
- 2031
- Routes
- TOPICAL
- Dosage Forms
- GEL
MIRVASO Approval History
What MIRVASO Treats
1 indicationsMIRVASO is approved for 1 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Rosacea
MIRVASO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to MIRVASO
3 of 12FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
12 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05270863 results posted | VT-002 | Ph 3 | completed | Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia |
| NCT03785340 results posted | OCU-310-301 | Ph 3 | completed | Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED) |
| NCT03591874 oGVHD results posted | OCU-300-301 | Ph 3 | terminated | Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease |
| NCT03760185 results posted | 18-1713 | Ph 2 | completed | Pupil Dilation for Treatment of IFIS |
| NCT03323164 results posted | 17-636E | Ph 4 | completed | Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study |
| NCT01959230 results posted | 861 | Ph 3 | completed | Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness |
| NCT01959243 results posted | 862 | Ph 3 | completed | Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants |
| NCT03966560 | KAEK-2014/04-74 | Ph 4 | completed | Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma |
| NCT03173365 BRIMOCAN | BRIMOCAN | Ph 2 | terminated | The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients |
| NCT02039765 | 863/13-100-0007 | Ph 1 | completed | Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%. |
| NCT02856919 BR14004 | BR.14.004 | Ph 4 | completed | A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. |
| NCT02568111 BRITE | NLD-PEG-14-10784 2015-002159-89 | Ph 4 | withdrawn | Brimonidine Tartrate for the Treatment of Injection Related Erythema |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
MIRVASO FDA Label Details
Indications & Usage
FDA Label (PDF)MIRVASO is indicated for the treatment of Rosacea.
Pro Intelligence Preview
Deep insights for MIRVASO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2031
- • 7 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 12 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.